CHEMOTHERAPY APR. 1979

Similar documents
CHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Kle

VOL.27 S-3 CHEMO THERAPY mido)-3-[[[1- (2-dimethylaminoethyl)-1H-tetrazol-5-yl] -thio] methyl]-ceph-3-em-4-carboxylic acid dihydro- S. aureus 209-P JC

CHEMOTHERAPY JUNE 1987 Table1 Media used *BHIB, brain heart infusion broth (Difco); /3 -NAD, S -nicotinamidoadeninedinucleotide (Sigma Chemical Co.);

CHEMOTHERAPY APR Fig. 1 Chemical structure of cefotetan (CTT, YM09330)

1272 CHEMOTHERAPY MAR. 1975



VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains )


988 CHEMOTHERAPY NOV. 1971

VOL. 28 S-2 CHEMOTHERAPY

CHEMOTHERAPY aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Prote

CHEMOTHERAPY

CHEMOTHERAPY NOV S. aureus, S. epidermidis, E. coli, K. pgeumoniae, E. cloacae, S. marcescens, P. mirabilis, Proteus, P. aeruginosa Inoculum siz

VOL.48 NO.7 lase negative staphylococci, Escherichia coli, Klebsiella spp., Citrobacter freundii, Enterobacter spp., indole-positive Proteus, Serratia

epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia

CHEMOTHERAPY APRIL 1992 Acinetobacter calcoaceticus Staphylococcus aureus, Escherichia coli P. aeruginosa E. eoli, Klebsiella pneumoniae Serratia marc

CHEMOTHERAPY JUNE 1986

CHEMOTHERAPY DEC Table 1 Antibacterial spectra of T-1982, CTT, CMZ, CTX, CPZ and CEZ 106 CFU/ml Note: P; Peptococcus, S; Streptococcus, G; Gaffk


Key Words: Klebsiella pneumoniae, CEP-AIS, MIC, "MBC", MIC of drugs in combination




Fig. 1 Chemical structure of DL-8280


CHEMOTHERAPY

Key words:fatty acid,plant oil,staphylococcus aureus,skin care, atopic dermatitis


CHEMOTHERAPY JUN Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter cloacae 27, Proteus rettgeri 7, Proteus inconstans 20, Proteus

CHEMO THE RAPY OCT. 1994


VOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity of gram nega

Fig.1 Chemical structure of BAY o 9867

CHEMOTHERAPY APR Fig. 2 The inactivation of aminoglycoside antibiotics by PC-904 Fig. 3 Serum concentration of PC-904 (1) Fig. 4 Urinary recover

Staphylococcus sp. K.pneumoniae P.mirabilis C.freundii E. cloacae Serratia sp. P. aeruginosa ml, Enterococcus avium >100ƒÊg/ml

CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin


coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, F


CHEMOTHERAPY

CHEMOTHERAPY SEPT. 1970


CHEMOTHERAPY FEB Table 1. Activity of cefpirome and others against clinical isolates

CHEMOTHERAPY 52 MAY d a a. Normal S. aureus d Đg/ml, 2h; e b b Đg/ml, Abnormal e. division lh; Abnormal thickening division cross f c. 1

Jan THE JAPANESE JOURNAL OF ANTIBIOTICS XL-1 Table 1. Outline of administering doses, routes and sampling times *: 4 ml/hr/kg Bacillus subtilis


VOL.47 NO.5 Table 1. Susceptibility distribution of Ĉ- lactams against clinical isolates of MRSA MRSA: rnethicillin- resistant Staphylococcus aureus

CHEMOTHERAPY Fig. 1 Chemical structure of CXM-AX

Key words: Disinfectants, Gram negative rods, Bactericidal effect P. aeruginosa 1, P. fluorescens 20 P. putida 179, P. cepacia 216 P. maltophilia 227,

1. Precise Determination of BaAl2O4 Cell and Certification of the Formation of Iron Bearing Solid Solution. By Hiroshi UCHIKAWA and Koichi TSUKIYAMA (

VOL. 34 S-2 CHEMOTH8RAPY 913

VOL. 37 NO. 3 Key words: Drug allergy, LMIT, Penams, Cephems, Cross-reactivity


VOL. 36 S-3 CHEMOTHERAPY 437

Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone


CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study

2108 CHEMOTHERAPY SEPT Table 1 Antimicrobial spectrum Fig. 1

VOL. 23 NO. 3 CHEMOTHERAPY 1379 Table 1 Susceptibility of clinical isolated strains to Tobramycin


VOL.35 S-2 CHEMOTHERAPY Table 1 Sex and age distribution Table 2 Applications of treatment with carumonam Table 3 Concentration of carumonam in human


The Phase Behavior of Monooleoylglycerol-Water Systems Mivoshi Oil & Fat Co.. Ltd. Faculty of Science and Technology, Science University of Tokyo Inst

CHEMOTHERAPY OCT Fig. 1 Chemical structure of CVA-K

Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Ent

Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS XXXVII (45)

CHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels of mezlocillin


1) K. J. Laidler, "Reaction Kinetics", Vol. II, Pergamon Press, New York (1963) Chap. 1 ; P. G. Ashmore, "Catalysis and Inhibition of Chemical Reactio


CHEMOTHERAPY FEB Table 1 Background of volunteers

A Nutritional Study of Anemia in Pregnancy Hematologic Characteristics in Pregnancy (Part 1) Keizo Shiraki, Fumiko Hisaoka Department of Nutrition, Sc


Key words: change serotype, Pseudomonas aeruginosa anti-pseudomonal drug,

Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates

VOL.30 S-1 CHEMOTHERAPY Table 1 Antibacterial activity of CTT against standard strains Table 2 Antibacterial activity of CTT against standard strains

dihydrostreptomycin(sm), sulfanilamide(sa), kanamycin(km), paromomycin(prm), fradiomycin(frm), ampicillin(apc), cephaloridine (CER), nalidixic acid(na

Introduction ur company has just started service to cut out sugar chains from protein and supply them to users by utilizing the handling technology of

Clostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile

VOL. 21 NO. 2 CHEMOTHERAPY 137

Fig. 1. Schematic drawing of testing system. 71 ( 1 )



Streptococcus pneumoniae,streptococcus pyogenes,streptococcus agalactiae,neisseria gonorrhoeae,h.influenzae,moraxella subgenus Branhamella catarrharis

Table1MIC of BAY o 9867 against standard strains

CHEMOTHERAPY APR. 1984

VOL. 40 S- 1 Table 1. Susceptibility of methicillin-resistant Staphylococcus aureus to meropenem Table 2. Coagulase typing of methicillin-resistant St

Fig. 1 The sketch of the neonatal intensive care unit in Tokyo Women's Medical College Hospital. (1979)

perature was about 2.5 Ž higher than that of the control irrespective of wind speed. With increasing wind speeds of more than 1m/s, the leaf temperatu

VOL.27 S-5 CHEMOTHERAPY Table 1 Clinical evaluations of cefamandole on UTI (1) Benign prostatic hypertrophy (2) Transurethral resection of bladder tum

On the nitrogen cycle and cultivable capacity of fish in the balanced aquarium By Aritsune SAEKI

CHEMOTHERAPY OCT. 1993

Key words: Surfactant, Tween, Legionella


THE JAPANESE JOURNAL OF ANTIBIOTICS 48-8 Enterococcus avium 5Š, Corynebacterium xerosis 10Š, Corynebacterium pseudodiphtheriticum 10Š, Corynebacterium

semen quality or those without WBC in semen. In the patients with azoospermia and normal FSH levels (normogonadotropic azzospermia), the antibody (IgG

Key words: E. coli O 157: H7, fosfomycin, verotoxin, mouse infection

udc-2.dvi

- 1 -

Transcription:

CHEMOTHERAPY APR. 1979

VOL.27 S-3 CHEMOTHERAPY

CHEMOTHERAPY APR. 1070 Table 1 Comparison of antibiotic susceptibility of bacteria with the capacity to degrade cefotiam and other cephalosporine by /3-lactamase Escherichia coli Klebsiella imeumoniae Proteus nzirabilis * A loopful of bacterial suspension (approximately 106 and 108 cells/m1) was inoculated. ** Approximately 108 cells in 1 ml of Trypticase soy broth(bbl) containing 0.2 //mole (approximately 100 AO of each antibiotic were incubated at 30 Ž for 1 hour. After the reaction was stopped by the addition of 4 volumes of methanol, the remaining activity of the antibiotic was determined by the paper disc method using B. subtilis PCl219 as a test organism. The degree of antibiotics degraded was expressed as follows : (-)0-5%, ( })6-20%, (+)21-50%, (œo)51-80%, ( )81-100%. *** CS 2911 and CS 2913 are resistant strains obtained from E. colt NIHJ JC-2 by repeated exposure to cefotiam and cefazolin respectively.

VOL.27 -S-3 CHEMOTHERAPY Table 1 Continued

CHEMOTHERAPY APR. 1079 Table 1 Continued

VOL. 27 S-3 CHEMOTHERAPY

CHEMOTHERAPY APR. 1979 Table 2 Hydrolysis of cefotiam and other eephalosporins by 13-lactamases * The bacteria grown to the late logarithmic phase in Trypticase soy broth (TSB; BBL), were incubated for 2 hours with(+) or without(-) 1mg (but 0.01 mg for S. aureus 1840 and 0.1mg for E. coli NIHJ JC-2, CS 2911 and CS 2913) of benzylpenicillin per ml of TSB to induce 19-lactamase. ** The sonic extract of bacterial cells except S. aureus for which culture filtrate was employed, was used as enzyme. The enzyme was incubated with 200 ILM of each substrate for 10 minutes and the reaction was stopped by the addition of 2 volumes of methanol. The enzyme activity was determined by the reduction of ultra violet absorption caused by the hydrolysis of the Ĉ-lactam bond of cephalosporins.

VOL. 27 S-3 CHEMOTHERAPY Table 2 Continued

CHEMOTHERAPY APR. 1979 Table 3 Kinetics of hydrolysis of cefotiam and several 13-lactam antibiotics by fl-lactamase * Vmax is expressed as relative rate of hydrolysis taking the rate for benzylpenicillin (penicillinase) or cephaloridine (cephalosporinase) as 100. ** R-plasmid mediated conjugatively transferable enzyme. Table 4 Ability of cefotiam and several cephalosporins to penetrate the outer membrane of Escherichia coli TN 713 and Klebsiella pneumoniae TN 1698 So: Antibiotic concentration in the reaction mixture Si: Calculated antibiotic concentration inside the outer membrane Vo: Velosity of antibiotic hydrolysis by sonically disrupted cell suspension Vi: Velosity of antibiotic hydrolysis by intact cells, which was corrected for the activity of leaked-out enzyme P: Permeability parameter

VOL. 27 S-3 CHEMOTHERAPY

CHEMOTHERAPY APR. 1979 9) HAMILTON-MILLER, J. M. T. Use of Michaelis-Menton kinetics in the analysis of synergism between $-lactam antibiotics. J. Theor. Biol. 31: 171,%476, 1971 10) ZIMMERMANN, W. & A. ROSSELET: Function of the outer membrane of Eschsrichia coil as a permeability barrier to beta-lactam antibiotics. Antimicrob. Agents & Chernoth. 12 368 `172, 1) RICHMOND, M. H. & R. B. SYKES: The 8- lactamasee of gram-negative bacteria and their physiological role. Adv. Microb. Physiol. 9 31'-88, 1973 2) BLUMBERG, P. M. & J. L. STROMINGER: Interaction of penicillin with the bacterial cell penicillin-binding proteins and penicillin-sensitive enzymes. Bacteriol. Rev. 38: 291 `335, 1974 3) COSTERTON, J. W. & K. J. CHENG: The role of bacterial cell envelope in antibiotic resistance. J. Antimicrob. Chemother. 1: 363 `377, 1975 4) COSTERTON, J. W.; J. M. INGRAM & K. J. CHENG: Structure and function of the cell envelope of gram-negative bacteria. Bacteriol. Rev. 38: 87 `110, 1974 5) NIICAIDO, H.: Biosynthesis and assembly of lipopolysaccharide and the outer membrane layer of gram-negative cell wall. in"bacterial membranes and walls", ed. by L. Leive, Marcel Dekker, Inc. New York, p. 131-'208 6) NEU, H. C.: The surface location of penicillinase in Escherichia coli and Salmonella typhimurium. Biochem. Biophys. Res. Commun. 32: 258-263, 1968 7) HAMILTON-MILLER, J. M. T.; J. T. SMITH & R. KNOX: Interaction of cephaloridine with penicillinase-producing gram-negative bacteria. Nature 208: 235-237, 1965 8) HAMILTON-MILLER, J. M. T.: Effect of EDTA upon bacterial permeability to benzylpenicillin. Biochem. Biophys. Res. Commun. 20 688 ` 691, 1965 1977 11) SAWAI, T.; K. MATSUBA & S. YAMAGISHI: A method for measuring the outer membrane. permeability of fl-lactam antibiotics in gramnegative bacteria. J. Antibiotics 30: 1134 ` 1136, 1977 12) SPRATT, B. G.: Properties of the penicillinbinding proteins of Escherichia coil K 12. Eur, J. Biochem. 72: 341 `352, 1977 13) NOVICK, R. P.: Analysis by transduction of mutations affecting penicillinase formation in Staphylococcus aureus. r J. Gen. Microbial. 33: 121 `136, 1963 15) LINEWEAVER, H. & D. BURK: The determination of enzyme dissociation constants. J. Amer. Chem. Soc. 56: 658 `666, 1934 16) NIKAIDO, H.; P. BAVOIL & Y. HIROTA: Outer membranes of gram-negative bacteria XV. Transmembrane diffusion rate in lipoproteindeficient mutants of Escherichia coll. J. Bacteriol. 132: 1045 `1047, 1977 17) NOZAKI, Y.; A. IMADA & M. YONEDA: SCE- 963, a new potent cephalosporin with high affinity for penicillin-binding proteins 1 and 3 of Escherichia coli. Antimicrob. Agents & Chemoth. (In preparation) 18) HAMILTON, T.E. & P.J. LAWRENCE: The formation of functional penicillin-binding proteins. J. Biol. Chem. 250: 6578 `6585, 1975

VOL. 27 S-3 CHEMOTHERAPY CEFOTIAM (SCE-963) STABILITY TO Ĉ-lactamase AND ABILITY TO PENETRATE THE OUTER MEMBRANE OF GRAM-NEGATIVE BACTERIA KENJI OKONOGI, MAKOTO KIDA and MASAHIKO YONEDA Central Research Division, Takeda Chemical Industries, Ltd. SUSUMU MITSUHASHI Department of Microbiology, School of Medicine, Gunma University The rate of hydrolysis of cefotiam (SCE-963) by cephalosporin j9-lactamases from various bacteria except Proteus vulgaris, was smaller than that of cefazolin, cephaloridine and cephalothin. Cefotiam as well as cefazolin and cephalothin, was hydrolysed more slowly than cephaloridine by penicillin 13-lactamases. When incubated with intact cells in the medium, cefotiam was more stable to degradation than cephaloridine and cefazolin but less stable than cephalothin. The ability of cefotiam to penetrate the outer membrane of Escherichia coli TN 713 and Klebsiella pneumoniae TN 1698 was estimated to be ten and two times greater than that of cephalothin and cefazolin, respectively, but smaller thanthat of cephaloridine. The calculated concentration of cefotiam inside the outer membrane of Escherichza coli TN 713 and Klebsiella pneumoniae TN 1698 was 35 to 37% and 10 to 17% of the concentration outside the cells, respectively, and was three to seventy times higher than that of cefazolin, cephaloridine and cephalothin.